<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166515">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910298</url>
  </required_header>
  <id_info>
    <org_study_id>LFC 2012.06.01</org_study_id>
    <nct_id>NCT01910298</nct_id>
  </id_info>
  <brief_title>Efficacy of Single Stage Breast Reconstruction</brief_title>
  <acronym>ESSBR</acronym>
  <official_title>A Prospective, Multicenter, Controlled Study of Implant-based Breast Reconstruction, Measuring the Safety, Efficacy and Outcomes, of Immediate Single Stage Breast Reconstruction With Strattice™ Reconstructive Tissue Matrix Versus Immediate Two Stage Breast Reconstruction Without Strattice™ TM .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeCell</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LifeCell</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>United Kingdom: National Institute for Health Research</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, non-randomised, parallel design comparing a primary
      Efficacy and primary Safety endpoint between subjects undergoing immediate post-mastectomy
      breast reconstruction with a breast implant and Strattice™ Reconstructive Tissue Matrix (TM)
      and subjects undergoing immediate, two-stage post-mastectomy breast reconstruction, where
      the initially placed expander will be exchanged for a breast implant only, without any type
      of reinforcement.

      The study objectives will be achieved by prospectively assessing the number of planned and
      unplanned post-mastectomy surgical interventions within 12 months of the mastectomy.

      Direct to Implant (DTI) breast reconstruction will include the use of Strattice™ TM for
      reinforcement of tissue during surgery.

      Two-stage breast reconstruction will include the initial placement of a tissue expander
      without mesh or flap reinforcement. The expander will be inflated over the next months, and
      then replaced with an implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, multicenter, non-randomised, parallel design will assess the clinical
      outcomes of immediate single-stage breast reconstruction, DTI, with support of Strattice™ TM
      compared to immediate, two-stage breast reconstruction without support of any mesh or
      autologous flap. The two-stage reconstruction control arm comprises initial expander
      placement, followed by exchange of expander to a permanent implant at 1 to a maximum of 6
      months after expander placement and fill.

      All subjects will be undergoing immediate post-mastectomy breast reconstruction with partial
      or full muscle coverage of the implant. Study subjects who need to undergo radiotherapy
      post-mastectomy, either planned or unplanned, are also allowed to participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of planned and unplanned post-mastectomy surgical interventions per subject</measure>
    <time_frame>Within 12 months of the initial study surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of breast-reconstruction related surgical complications</measure>
    <time_frame>At 6 and 12 months post-mastectomy and 24 months post-permanent reconstruction</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysed per breast and per subject.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of planned and unplanned post-mastectomy surgical interventions</measure>
    <time_frame>At 6 months post-mastectomy and at 24 months post-permanent reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per breast and per subject</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life of subjects</measure>
    <time_frame>At 3, 6, and 12 months post-mastectomy and at 24 months post-permanent reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured through questionnaires (EQ-5D and Breast-Q) and time to return to work or normal daily activities.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospital/clinic visits</measure>
    <time_frame>At 6 and 12 months post-mastectomy and at 24 months post-permanent reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per subject, including expansion visits in the two stage reconstruction arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall breast-mound reconstruction</measure>
    <time_frame>At 24 months post-permanent reconstruction</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>From initial surgery to surgeon-subject agreement that reconstruction is complete.</description>
  </other_outcome>
  <other_outcome>
    <measure>Aesthetic outcomes of subjects</measure>
    <time_frame>At 12 months post-mastectomy at 12 months post-mastectomy and at 24 months post-permanent reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded assessment of 2D photographs by an independent reviewer panel</description>
  </other_outcome>
  <other_outcome>
    <measure>Surgeon satisfaction scores of subjects</measure>
    <time_frame>At 6 and 12 months post-mastectomy and 24 months post-permanent reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject satisfaction scores</measure>
    <time_frame>At 6 and 12 months post-mastectomy and 24 months post-permanent reconstruction</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject assessment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mastectomy and Breast Reconstruction</condition>
  <arm_group>
    <arm_group_label>Breast reconstruction, direct to implant with Strattice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects undergoing immediate post-mastectomy breast reconstruction with a breast implant and Strattice™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two stage breast reconstruction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects undergoing immediate, two-stage post-mastectomy breast reconstruction without reinforcement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast reconstruction, direct to implant with Strattice</intervention_name>
    <arm_group_label>Breast reconstruction, direct to implant with Strattice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two stage breast reconstruction</intervention_name>
    <arm_group_label>Two stage breast reconstruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female 18 years or older

          2. A candidate for both arms of the study involving immediate breast reconstruction
             post-skin sparing mastectomy (unilateral or bilateral) (DTI with the use of Strattice
             TM, 2 stage with use of Tissue Expander through exchange to Implant without support
             of a mesh or autologous tissue)

          3. An American Society of Anesthesiologists (ASA) Physical Status Classification of 1 or
             2

          4. Estimated life expectancy &gt; 3 years

          5. Able and willing to return for all scheduled and required study visits

          6. Able to provide written informed consent for study participation

        Exclusion Criteria:

          1. Clinically significant systemic disease, as determined by the Investigator, which
             could affect study participation or study results

          2. Received neo-adjuvant, inductive chemo-therapy (except Herceptin, or other targeted
             therapy) within 4 weeks prior to mastectomy

          3. Previous radiation therapy to either breast at any time

          4. Predicted implant size that is greater than or equal to 500 gms, per Investigator
             assessment

          5. BMI &lt;17 or &gt; 30

          6. Co-morbid factors which predispose to postoperative infection, e.g. diabetes,
             collagen vascular disease, chronic steroid (except inhalers)/immunosuppressant use,
             immune deficiency, or co-existent infection

          7. Pregnant or lactating

          8. 3rd degree ptosis

          9. Prior breast surgery including: breast reduction, augmentation, mastopexy,
             quadrectomy, and partial mastectomy with reduction of the skin envelope

         10. Prior use of a device (mesh or matrix) in the Breast

         11. Concomitant unrelated condition of breast/chest wall/skin that, as determined by the
             investigator, could adversely affect the surgical outcome (e.g. significant chest
             wall abnormalities including pectus excavatum or pectus carinatum)

         12. Planned autologous tissue flap in addition to prosthetic implant

         13. Use of permanent expander implants such as Becker expanders or the Natrelle
             Anatomical Permanent expander 150

         14. Current alcohol abuse, illicit drug use, significant mental illness, physical
             dependence to any opioid, or drug abuse or addiction

         15. Currently enrolled or plans to enroll in another clinical trial unless it is: a
             registry, a retrospective study, a neo-adjuvant chemotherapy trial (as long as the
             chemotherapy regimen has been stopped 4 weeks prior to mastectomy), or a
             hormone/anti-hormonal therapy trial

         16. Any of the conditions identified within the labeled contraindications, i.e.
             sensitivity to porcine derived products or polysorbate 20.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Karl Breuing</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interdisciplinary Breast Center - Clinic for Senology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karl Breuing, MD, FACS</last_name>
    <phone>+49 201 17433509</phone>
    <email>k.breuing@kliniken-essen-mitte.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Marion Fournier, MD</last_name>
      <phone>+33 556 333 335</phone>
      <email>m.fournier@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr. Marion Fournier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Marie-Pierre Chauvet, MD</last_name>
      <phone>+ 33 3 20 29 59 06</phone>
      <email>mp-chauvet@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Dr. Marie-Pierre Chauvet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes, Saint Herblain, Cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Virginie Bordes, MD</last_name>
      <phone>+33 2 40 67 99 28</phone>
      <email>Virginie.Bordes@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr. Virginie Bordes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Michael Atlan</last_name>
    </contact>
    <investigator>
      <last_name>Dr Michael Atlan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L'Institut du Sein- Paris Breast Center</name>
      <address>
        <city>Paris</city>
        <zip>75116</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Krishna Clough, MD</last_name>
      <phone>+ 33 1 45 63 00 00</phone>
      <email>krishna.clough@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Dr. Krishna Clough</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PD Dr. med. Michael Lux, MD</last_name>
      <phone>+49 9131 85-33553</phone>
      <email>Michael.Lux@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>PD Dr. med. Michael Lux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum klinikum, Alfried Krupp Krankenhaus,</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Karl Breuing, MD, FACS</last_name>
      <phone>+49 201 17433509</phone>
      <email>k.breuing@kliniken-essen-mitte.de</email>
    </contact>
    <investigator>
      <last_name>Dr. Karl Breuing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OA Dr. med. Ursula Hille-Betz, MD</last_name>
      <phone>+49511/532-9563</phone>
      <email>Hille-Betz.Ursula@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>OA Dr. med. Ursula Hille-Betz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. med. Florian Schütz</last_name>
      <phone>+49 6221 563 7688</phone>
      <email>florian.schuetz@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Dr. med. Florian Schuetz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. med. Stefan Päpke, MD</last_name>
      <phone>+49 89 41405433</phone>
      <email>Stefan.Paepke@lrz.tum.de</email>
    </contact>
    <investigator>
      <last_name>Dr. med. Stefan Paepke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik der Universität München, Campus Innenstadt</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PD Dr. med. Darius Dian, MD</last_name>
      <phone>+49 89 5160 4111</phone>
      <email>Darius.Dian@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>PD Dr. med. Darius Dian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Paulinen Klinik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65197</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heyl, MD</last_name>
      <phone>+49 611 847 2391</phone>
      <email>v.heyl@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Dr. med. Volker Heyl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Luke's hospital / Bradford Royal Infirmary (BRI)</name>
      <address>
        <city>Bradford</city>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr. Rick Linforth</last_name>
      <phone>+44 1274 383787</phone>
      <email>Richard.Linforth@bthft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mr. Richard Linforth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Mike Dixon</last_name>
      <phone>+44 131 537 2643</phone>
      <email>jmd@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Prof. Mike Dixon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr. Raouf Daoud</last_name>
      <phone>+44 7951705595</phone>
      <email>raouf.daoud@fph-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mr. Raouf Daoud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr. Douglas Macmillan</last_name>
      <phone>+44 115 969 1169</phone>
      <email>Douglas.Macmillan@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mr. Douglas Macmillan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital UHSM NHS Foundation Trust</name>
      <address>
        <city>Wythenshawe Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr. Richard , Johnson</last_name>
      <phone>+44 (0)161 291 4432</phone>
      <email>richard.johnson@UHSM.NHS.UK</email>
    </contact>
    <investigator>
      <last_name>Mr. Richard Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast reconstruction</keyword>
  <keyword>Breast implant</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Mastectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
